Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Spencer, Michael ^a   Yang, Lin ^b   Adu, Akosua ^a   Finlin, Brian S ^a   Zhu, Beibei ^a   Shipp, Lindsey R ^a   Rasouli, Neda ^d   Peterson, Charlotte A ^c   Kern, Philip A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLLAGEN; DOCOSAHEXAENOIC ACID; ELASTIN; FISH OIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CAPILLARY DENSITY; CARBOHYDRATE METABOLISM; CELL DEATH; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MACROPHAGE; MALE; MAST CELL; OBESITY; ORAL GLUCOSE TOLERANCE TEST; VASCULARIZATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADIPOCYTES; ADIPOSE TISSUE; ADULT; ELASTIN; FEMALE; FISH OILS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; MALE; MAST CELLS; MIDDLE AGED; OBESITY; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84904267250     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102190     Document Type: Article

References (51)

1. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, et al. (2010) Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 299: E1016-E1027.
2. Pasarica M, Gowronska-Kozak B, Burk D, Remedios I, Hymel D, et al. (2009) Adipose tissue collagen VI in obesity. J Clin Endocrinol Metab 94: 5155-5162.
3. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, et al. (2009) Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 58: 718-725.
4. Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE, Jr., et al. (2011) Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab 96: E1990-E1998.
5. Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and obesity. J Clin Invest 121: 2094-2101.
6. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, et al. (2005) Expression of CD68 and Macrophage Chemoattractant Protein-1 Genes in Human Adipose and Muscle Tissues: Association With Cytokine Expression, Insulin Resistance, and Reduction by Pioglitazone. Diabetes 54: 2305-2313. (Pubitemid 41134256)
7. Bodles AM, Varma V, Yao-Borengasser A, Phanavanh B, Peterson CA, et al. (2006) Pioglitazone induces apoptosis of macrophages in human adipose tissue. J Lipid Res 47: 2080-2088. (Pubitemid 44401997)
8. Consoli A, Devangelio E (2005) Thiazolidinediones and inflammation. Lupus 14: 794-797. (Pubitemid 41413314)
9. Staels B, Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470. (Pubitemid 41134276)
10. Fritsche K (2006) Fatty acids as modulators of the immune response. Annu Rev Nutr 26: 45-73.
11. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83: 1505S-1519S.
12. Spencer M, Finlin BS, Unal R, Zhu B, Morris AJ, et al. (2013) Omega-3 Fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes 62: 1709-1717.
13. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, et al. (2006) Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 55: 924-928. (Pubitemid 44100165)
14. Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, et al. (2009) Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 296: E480-E489.
15. Zhang J, Shi GP (2012) Mast cells and metabolic syndrome. Biochim Biophys Acta 1822: 14-20.
16. Liu J, Divoux A, Sun J, Zhang J, Clement K, et al. (2009) Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 15: 940-945.
17. Divoux A, Moutel S, Poitou C, Lacasa D, Veyrie N, et al. (2012) Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. J Clin Endocrinol Metab 97: E1677-E1685.
18. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, et al. (2005) Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288: E930-E934. (Pubitemid 40547887)
19. Rasouli N, Kern PA, Reece EA, Elbein SC (2006) Effects of pioglitazone and metformin on {beta}-cell function in non-diabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab.
20. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA (2006) Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 290: E42-E46.
21. Rasouli N, Kern PA, Reece EA, Elbein SC (2007) Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab 292: E359-E365. (Pubitemid 46052962)
22. Das SK, Chu WS, Mondal AK, Sharma NK, Kern PA, et al. (2008) Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines. Am J Physiol Endocrinol Metab 295: E393-E400.
23. Unal R, Yao-Borengasser A, Varma V, Rasouli N, Labbate C, et al. (2010) Matrix Metalloproteinase-9 Is Increased in Obese Subjects and Decreases in Response to Pioglitazone. J Clin Endocrinol Metab.
24. Rasouli N, Kern PA, Elbein SC, Sharma NK, Das SK (2012) Improved insulin sensitivity after treatment with PPARgamma and PPARalpha ligands is mediated by genetically modulated transcripts. Pharmacogenet Genomics 22: 484-497.
25. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, et al. (2003) MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5: 1003-1015. (Pubitemid 38009940)
26. Bergman RN, Prager R, Volund A, Olefsky JM (1987) Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790-800. (Pubitemid 17050904)
27. Mula J, Lee JD, Liu F, Yang L, Peterson CA (2013) Automated image analysis of skeletal muscle fiber cross-sectional area. J Appl Physiol 114: 148-155.
28. Di Cataldo S, Ficarra E, Acquaviva A, Macii E (2010) Automated segmentation of tissue images for computerized IHC analysis. Comput Methods Programs Biomed 100: 1-15.
29. Smolle J (1996) Optimization of linear image combination for segmentation in red-green-blue images. Anal Quant Cytol Histol 18: 323-329.
30. Koenen TB, Tack CJ, Kroese JM, Hermus AR, Sweep FC, et al. (2009) Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. J Clin Endocrinol Metab 94: 4453-4457.
31. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, et al. (2002) Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51: 30-36. (Pubitemid 34517976)
32. McLaughlin TM, Liu T, Yee G, Abbasi F, Lamendola C, et al. (2010) Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. Obesity (Silver Spring) 18: 926-931.
33. Smith SR, Xie H, Baghian S, Needham A, McNeil M, et al. (2006) Pioglitazone changes the distribution of adipocyte size in type 2 diabetics. Adipocytes 2: 11-22.
34. Shadid S, Jensen MD (2003) Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26: 3148-3152. (Pubitemid 37339512)
35. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77: 289-312.
36. Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, et al. (2009) Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 94: 4619-4623.
37. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, et al. (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54: 2277-2286. (Pubitemid 41134253)
38. Klimcakova E, Roussel B, Kovacova Z, Kovacikova M, Siklova-Vitkova M, et al. (2011) Macrophage gene expression is related to obesity and the metabolic syndrome in human subcutaneous fat as well as in visceral fat. Diabetologia 54: 876-887.
39. Miyazaki Y, Matsuda M, DeFronzo RA (2002) Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25: 517-523. (Pubitemid 41103346)
40. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, et al. (2004) Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes. Diabetes 53: 1621-1629. (Pubitemid 38697679)
41. Rasouli N, Kern PA (2008) Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93: S64-S73.
42. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, et al. (2007) Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects. Arterioscler Thromb Vasc Biol.
43. Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, et al. (2009) Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. J Diabetes Complications.
44. Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, et al. (2007) Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 56: 1418-1424. (Pubitemid 47404606)
45. Koppaka S, Kehlenbrink S, Carey M, Li W, Sanchez E, et al. (2013) Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans. Diabetes 62: 1843-1854.
46. Odegaard JI, Ricardo-Gonzalez RR, Red EA, Vats D, Morel CR, et al. (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7: 496-507. (Pubitemid 351729205)
47. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, et al. (2007) PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6: 137-143. (Pubitemid 47189091)
48. Chawla A (2010) Control of macrophage activation and function by PPARs. Circ Res 106: 1559-1569.
49. Lawrence T, Natoli G (2011) Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 11: 750-761.
50. Lee BC, Lee J (2013) Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta.
51. Elbein SC, Kern PA, Rasouli N, Yao-Borengasser A, Sharma NK, et al. (2011) Global Gene Expression Profiles of Subcutaneous Adipose and Muscle From Glucose-Tolerant, Insulin-Sensitive, and Insulin-Resistant Individuals Matched for BMI. Diabetes 60: 1019-1029.